Cefazolin plus minocycline against a clinical isolate of Vibrio vulnificus: In vitro and animal studies

Japanese Journal of Infectious Diseases

Volumn 63, Issue 1, 2010, Pages 16-18

  Tang, Hung Jen ^a   Ko, Wen Chien ^b   Chuang, Yin Ching ^a   Chen, Chi Chung ^a   Chiang, Shyh Ren ^a  

^a CHI MEI MEDICAL CENTER   (Taiwan)

^b NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CEFAZOLIN; CYCLOPHOSPHAMIDE; MINOCYCLINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBACTERIAL ACTIVITY; ARTICLE; BAGG ALBINO MOUSE; COLONY FORMING UNIT; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; FEMALE; IN VITRO STUDY; MOUSE; NEUTROPENIA; NONHUMAN; TREATMENT RESPONSE; VIBRIO VULNIFICUS; VIBRIO VULNIFICUS INFECTION;

ANIMALS; ANTI-BACTERIAL AGENTS; CEFAZOLIN; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MICE; MICE, INBRED BALB C; MICROBIAL SENSITIVITY TESTS; MICROBIAL VIABILITY; MINOCYCLINE; SURVIVAL ANALYSIS; TIME FACTORS; VIBRIO INFECTIONS; VIBRIO VULNIFICUS;

EID: 76649137974     PISSN: 13446304     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Chuang, Y.C., Yuan, C.Y., Liu, C.Y., et al. (1992): Vibrio vulnificus infection in Taiwan: report of 28 cases and review of clinical manifestations and treatment. Clin. Infect. Dis., 15, 271-276.
2. Dalsgaard, A., Frimodt-Møller, N., Bruun, B., et al. (1996): Clinical manifestations and molecular epidemiology of Vibrio vulnificus infections in Denmark. Eur. J. Clin. Microbiol. Infect. Dis., 15, 227-232.
3. Chuang, Y.C., Young, C. and Chen, C.W. (1989): Vibrio vulnificus infection. Scand. J. Infect. Dis., 21, 721-726.
4. Liu, J.W., Tang, H.J. and Chuang, Y.C. (2006): Prognostic factors and antibiotics in Vibrio vulnificus septicemia. Arch. Intern. Med., 166, 2117-2123.
5. Morris, J.G., Jr. and Tenney, J. (1985): Antibiotic therapy for Vibrio vulnificus infection. JAMA, 253, 1121-1122.
6. Bowdre, J.H., Hull, J.H. and Cocchetto, D.M. (1983): Antibiotics efficacy against Vibrio vulnificus in the mouse: superiority of tetracycline. J. Pharmacol. Exp. Ther., 225, 595-598.
7. Hsueh, P.R., Chang, J.C., Chang, S.C., et al. (1995): In vitro antimicrobial susceptibility of Vibrio vulnificus isolated in Taiwan. Eur. J. Clin. Microbiol. Infect. Dis., 14, 151-153.
8. French, G.L., Woo, M.L., Hui, Y.W., et al. (1989): Antimicrobial susceptibilities of halophilic vibrios. J. Antimicrob. Chemother., 24, 183-194.
9. Tang, H.J., Chang, M.C., Ko, W.C., et al. (2002): In vitro and in vivo activities of newer fluoroquinolones against Vibrio vulnificus. Antimicrob. Agents Chemother., 46, 3580-3584.
10. Fang, F.C. (1992): Use of tetracycline for treatment of Vibrio vulnificus infections. Clin. Infect. Dis., 15, 1071-1072.
11. Chuang, Y.C., Liu, J.W., Ko, W.C., et al. (1997): In vitro synergism between cefotaxime and minocycline against Vibrio vulnificus. Antimicrob. Agents Chemother., 41, 2214-2217.
12. Chuang, Y.C., Ko, W.C., Wang, S.T., et al. (1998): Minocycline and cefotaxime in the treatment of experimental murine Vibrio vulnificus infection. Antimicrob. Agents Chemother., 42, 1319-1322.
13. National Committee for Clinical Laboratory Standards (2000): Methods for dilution antimicrobial susceptibility testing for bacteria that grow aerobically. Approved standard-5th ed. M7-A5. NCCLS, Villanova, Pa.
14. Woodnutt, G., Berry, V. and Mizen, L. (1992): Simulation of human serum pharmacokinetics of cefazolin, piperacillin, and BRL 42715 in rats and efficacy against experimental intraperitoneal infections. Antimicrob. Agents Chemother., 36, 1427-1431.
15. Matsui, H., Yano, K. and Okuda, T. (1982): Pharmacokinetics of the cephalosporin SM-1652 in mice, rats, rabbits, dogs, and rhesus monkeys. Antimicrob. Agents Chemother., 22, 213-217.
16. Iwahi, T. and Tsuchiya, K. (1980): Comparative activities of cefotiam and cefazolin against urinary tract infection with Proteus mirabilis in mice. Antimicrob. Agents Chemother., 18, 257-263.
17. Frimodt-Møller, N. and Knudsen, J.D.(1999): Handbook of Animal Models of Infection. Experimental Models in Antimicrobial Chemotherapy. Chapter 14. Academic Press, New York.